Sorry, just realised I completely ignored revenues from TGA provisional approval in Australia. I think the value of this early revenue is not for valuation purposes (let's face it, it's peanuts compared to the the US +Europe market), but rather the early cash flow it brings and avoiding any future need for dilutive CRs to pursue other indications. It also offers the company valuable practice in marketing and negotiating distribution deals with big pharma. If they are going to make mistakes, I'd rather them make it in the Australian market and learn from that experience.
Sorry, just realised I completely ignored revenues from TGA...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
-0.005(2.04%) |
Mkt cap ! $83.98M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.5¢ | 24.0¢ | $202.2K | 814.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 181098 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 118621 | 5 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |